Nanogen (NGEN) Reports Q2 Loss of $0.07
More News related to NGEN
- Nanogen (NGEN) Reports a Q3 Loss; FY Guidance Unchanged
- Nanogen (NGEN) and The Elitech Group Announce Merger Agreement
- Nanogen (NGEN) Reports Q2 Loss of $0.07
- Nanogen (NGEN) Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu
- Nanogen (NGEN) Announces Consolidation of Point of Care Manufacturing Operations
More News related to Earnings
- Raytheon (RTN) Awarded $241.3M U.S. Navy Contract for DDG 1000 Architect Software
- Microsoft and Murdoch's News Corp Discussing Google Workaround
- General Cable (BGC) Provides Update to Antitrust and Competition Law Investigations
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Kratos Defense & Security (KTOS) Awarded $1.4M U.S. Dept. of Labor Task Order
Nanogen, Inc. (Nasdaq: NGEN) reports a Q2 loss of $0.07, compared to a $0.20 loss in the same quarter last year. Revenues for the quarter were $12.9 million, versus $10.7 million in Q207.
Nanogen, Inc., a diagnostics company, engages in developing, manufacturing, and selling diagnostic products for use in the in vitro diagnostic market in the United States, Canada, and Europe.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
